LABETALOL
Vessels; Occlusion
Hamilton Health Sciences CorporationSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Vessels; Occlusion cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lipitor Zhongda Hospital | Phase 4 | BB |
Clevidipine ProMedica Health System | Phase 3 | BB |
Compound Edaravone Beijing Tiantan Hospital | Phase 3 | BB |
Tirofiban Xiang Luo | Phase 2/3 | B |
Arestin Xiang Luo | Phase 2/3 | B |
Hydralazine Hamilton Health Sciences Corporation | Phase 2 | B |
Enalapril Hamilton Health Sciences Corporation | Phase 2 | B |
Same molecule, other indications
LABETALOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →